The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
A definitive model for predicting absolute risk of coronary heart disease (CHD) in male and female people with Type II diabetes is not yet available. This paper provides an equation for estimating the risk of new CHD events in people with Type II diabetes, based on data from 4540 U.K. Prospective Diabetes Study male and female patients. Unlike previously published risk equations, the model is diabetes-specific and incorporates glycaemia, systolic blood pressure and lipid levels as risk factors, in addition to age, sex, ethnic group, smoking status and time since diagnosis of diabetes. All variables included in the final model were statistically significant (P<0.001, except smoking for which P=0.0013) in likelihood ratio testing. This model provides the estimates of CHD risk required by current guidelines for the primary prevention of CHD in Type II diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The lower the CAD risk, the higher the chance of a false positive”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [248]
In the citing paper
“During the entire follow-up period, the rate of death among patients in the conventionaltherapy group was 50%, a finding that underscores the poor prognosis for such patients in the absence of intensive treatment.20”
From Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) · cites this paper as [20]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Cited by
Items 701–800 of 1,000
Ushigome, E., Kitagawa, N., Kitagawa, N., Tanaka, T., Hasegawa, G., Ohnishi, M., Tsunoda, S., Ushigome, H., Yokota, I., Nakamura, N., et al. (2020) · Hypertension Research · doi:10.1038/s41440-020-00584-z · Cited by 13
“Our study showed that lower SBP was associated with lower risks of cardiovascular outcomes, which is in accordance with previous studies [14, 15].”
ResultTimofticiuc, D. C. P., Vladu, I. M., Ștefan, A. G., Clenciu, D., Mitrea, A., Pădureanu, V., Efrem, I. C., Diaconu, I.-D., Turcu, A. A., Ţenea-Cojan, T. Ş., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154403 · Cited by 13
Shah, N. D., Mason, J. E., Kurt, M., Denton, B. T., Schaefer, A. J., Montori, V. M., & Smith, S. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016170 · Cited by 13
“[11,12,13] These probabilities depend on health states and age, and reflect the changes in the patient’s health and medical treatment status.”
BackgroundPrediction of Cardiovascular Disease Events
Wilson, P. W. F. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.10.004 · Cited by 14
“The investigators have reported that the key predictor variables for initial CHD events were age, diabetes duration, presence of atrial fibrillation, glycosylated hemoglobin level, systolic blood pressure level, total cholesterol concentration, HDL-cholesterol concentration, race, and smoking status.(38) European grou…”
BackgroundNutrition in an ethnically diverse society: what are some of the key challenges?
Szczepura, A. K. (2011) · Proceedings of The Nutrition Society · doi:10.1017/s0029665111000085 · Cited by 15
Lipoproteins and other Risk Factors for Cardiovascular Disease in a Student Population
Pap, D., Čolak, E., Majkić‐Singh, N., Grubor‐Lajšić, G., & Vicković, S. (2013) · Journal of Medical Biochemistry · doi:10.2478/jomb-2013-0002 · Cited by 13
“Indeed, each 1% increase in HDL-c concentration has been associated with a 2–4% decrease in the risk for coronary heart disease (20, 21), while an increase of LDL-c concentration of 1 mmol/L leads to increased risk for ischemic heart disease (IHD) by 57% (22).”
BackgroundKhachatryan, L., Scharpf, R. B., & Kagan, S. H. (2011) · Health Care For Women International · doi:10.1080/07399332.2011.569041 · Cited by 13
Taveira, T. H., Pirraglia, P. A., Cohen, L. B., & Wu, W.-C. H. (2008) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.00008.x · Cited by 14
Yang, X., Kong, A. P. S., So, W. Y., Ronald, C. W., Ho, C. S., Lam, C. W. K., Chow, C. C., Cockram, C. S., Tong, P. C. Y., & Chan, J. C. N. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.675 · Cited by 13
“drug effects on diabetic complications were expected to be consistent with their beneficial effects on risk profile [31], drug use after the baseline was used as covariates except for insulin, where the total number of years of insulin usage was used as the covariate.”
BackgroundSmolen, H. J., Murphy, D. R., Gahn, J. C., Yu, X., & Curtis, B. H. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.9.968 · Cited by 14
Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives
de Vries, J. K., Levin, A., Loud, F. C., Adler, A., Mayer, G. J., & Pena, M. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13412 · Cited by 14
Self-citationJohn, J. R., Jones, A., Neville, A. M., Ghassempour, S., Girosi, F., & Tannous, K. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062164 · Cited by 14
Kizer, J. R., Krauser, D. G., Rodeheffer, R. J., Burnett, J. C. J., Okin, P. M., Roman, M. J., Umans, J. G., Best, L. G., Lee, E. T., & Devereux, R. B. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.03.026 · Cited by 13
Llauradó, G., Cano, A., Hernández, C., González-Sastre, M., Rodríguez, A.-A., Puntí, J., Berlanga, E., Albert, L., Simó, R., Vendrell, J. J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174640 · Cited by 14
McQueen, R. B., Breton, M. D., Craig, J., Holmes, H., Whittington, M. D., Ott, M. A., & Campbell, J. D. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818769098 · Cited by 12
Seon, C. S., Min, K. W., Lee, S. Y., Nho, K. W., Park, S. H., Koo, B. K., & Han, K. A. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.6.619 · Cited by 12
On behalf of REPOSI Investigators, Bertolotti, M., Franchi, C., Rocchi, M., Miceli, A., Libbra, M. V., Nobili, A., Lancellotti, G., Carulli, L., & Mussi, C. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0448-8 · Cited by 12
Ban, J.-W., Wallace, E., Stevens, R., & Perera, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179102 · Cited by 12
Self-citationWang, X., Cui, N., Liu, X., & Liu, X. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.04.006 · Cited by 12
Koo, B. K., Park, S. H., Han, K., & Moon, M. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1197 · Cited by 12
Cardiovascular disease in type 2 diabetes: Attributable risk due to modifiable risk factors.
Zeber, J. E., & Parchman, M. L. (2010) · PubMed · Cited by 22
Generation of Knowledge for Clinical Decision Support
Matheny, M. E., & Lucila Ohno-machado, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398476-0.00011-7 · Cited by 12
Kim, Y., Jeong, I., Kim, S. G., Cho, D. H., Kim, C. H., Kim, C. S., Lee, W., Won, K. C., Cha, J.-H., Lee, J., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0251 · Cited by 14
“The United Kingdom Prospective Diabetes Study Risk Engine score [14] can also be computed to detect the risk for CVD.”
BackgroundThe metabolic syndrome: An exercise in utility or futility?
SADIKOT, S. M., & Misra, A. (2007) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2006.11.001 · Cited by 14
Engel, S. S., Anderson, K. M., Hanson, Musliner, & Steinberg, H. O. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s44330 · Cited by 12
“3 In the UK Prospective Diabetes Study, a 57% increased risk of coronary heart disease was reported for every 1 mmol/L increment in LDL-C.”
Hernáez, R., Choque, L., Giménez, M., Costa, Á., Márquez, J. I., & Conget, I. (2004) · Revista Española de Cardiología · doi:10.1016/s0300-8932(04)77149-3 · Cited by 12
Cardiovascular risk prediction in adults with type 1 diabetes: The Fremantle Diabetes Study
Davis, W. A., & Davis, T. M. E. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.09.015 · Cited by 12
After the diabetes care trial ends, now what? A 1-year follow-up of the RxING study
Hamarneh, Y. N. A., Sauriol, L., & Tsuyuki, R. T. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008152 · Cited by 12
“If maintained, this change from baseline has the potential to have a significant impact on future diabetes-related complications.(7) This study is not without limitations.”
BackgroundBalducci, S., Conti, F., Sacchetti, M., Russo, C. R., Argento, G., Haxhi, J., Orlando, G., Rapisarda, G., D’Errico, V., Cardelli, P., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027429 · Cited by 13
Hobbs, R. F., Khan, T., & Collins, B. (2005) · Europe PMC (PubMed Central) · Cited by 12
Frison, V., Simioni, N., Marangoni, A., Balzano, S., Vinci, C., Zenari, L., De Moliner, L., Tadiotto, F., D’Ambrosio, M., Confortin, L., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0503-4 · Cited by 12
Validación de tres ecuaciones de riesgo coronario en población diabética de un centro de salud
Cañón-Barroso, L., Muro, E. C., Ochoa, G. F., Hernández, T. N., García-Vellido, A., & Buitrago, F. (2006) · Medicina Clínica · doi:10.1157/13086846 · Cited by 20
Using Repeated Measurements to Predict Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus
Gokhale, K. M., Chandan, J. S., Sainsbury, C. A. R., Peter Tiňo, B., Tahrani, A. A., Toulis, K. A., & Nirantharakumar, K. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.10.008 · Cited by 11
Pinto, D. (2011) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v27i1.10831 · Cited by 11
Tandon, S., Wackers, F. J. T., Inzucchi, S. E., Bansal, S., Staib, L. H., Chyun, D. A., Davey, J. A., Young, L. H., & for the DIAD Investigators (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111431470 · Cited by 11
Stevens, S. R., Segar, M. W., Pandey, A., Lokhnygina, Y. V., Green, J. B., McGuire, D. K., Standl, E., Peterson, E. D., & Holman, R. R. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01603-8 · Cited by 12
“Finally, the UKPDS Risk Engine was developed using data collected between 1977 and 1991 from individuals with newly diagnosed T2DM aged 25–65, and may not reflect the current landscape of medical practices and burden of disease seen in individuals with long-standing T2DM, especially those with established ASCVD [5].”
MethodZondag, A. G. M., Groenhof, T. K. J., van der Graaf, R., van Solinge, W. W., Bots, M. L., Haitjema, S., UCC-CVRM study group, de Jong, P. A., Verhaar, M. C., Visseren, F. L. J., et al. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-01924-6 · Cited by 12
“Absolute 10-year risk scores for cardiovascular disease (CVD) morbidity and mortality were calculated for each patient using prevailing algorithms at the time of the start of UCCCVRM, being either the SCORE risk model (SCORENL) [17], United Kingdom Prospective Diabetes Study risk score (UKPDS) [18], or the Second Mani…”
MethodTuthill, A., Quinn, A., McColgan, D., McKenna, M. J., O'Shea, D. B., & McKenna, T. J. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00731.x · Cited by 11
DeGuzman, P. B., Akosah, K. O., Simpson, A. G., Barbieri, K. E., Megginson, G. C., Goldberg, R. I., & Beller, G. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111431471 · Cited by 11
Menon, R. K., Rickard, A. P., Mannan, N., Timms, P. M., Sharp, S. J., Martineau, A. R., Boucher, B. J., Chowdhury, T. A., Griffiths, C., Griffin, S. J., et al. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-999 · Cited by 15
“There are multiple secondary endpoints including systolic and diastolic blood pressure, random cholesterol, HDL cholesterol, ApoA1 and ApoB apolipoproteins, CVD risk score as assessed by the UKPDS risk engine (version 2) [42] and additionally in London only, a measurement of arterial stiffness assessed by pulse wave v…”
MethodEchouffo-Tcheugui, J. B., Ogunniyi, M. O., & Kengne, A. P. (2011) · ISRN Cardiology · doi:10.5402/2011/242656 · Cited by 12
“inclusion in diabetes-specific tools as two parameters: age at diagnosis of diabetes and duration of diabetes [29].”
BackgroundMethodChoi, H. Y., Lim, H.-S., Kim, Y. H., Jeon, H. S., Kim, M. J., Lee, S. H., Jung, J. H., Lee, Y. K., Kim, H. J., & Bae, K. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.980886 · Cited by 11
“Diarrhea 0(0) 1(1) 0(0) 0(0) 1(1) Dyspepsia 0(0) 1(1) 0(0) 0(0) 1(1) Nausea 0(0) 1(1) 0(0) 1(1) 2(2) Oropharyngeal pain 0(0) 1(1) 1(1) 1(1) 3(3) Vomiting 0(0) 1(1) 0(0) 0(0) 1(1) Fatigue 0(0) 0(0) 1(1) 2(2) 2(3) Pyrexia 0(0) 0(0) 1(1) 0(0) 1(1) Hyperbilirubinemia 0(0) 0(0) 1(1) 0(0) 1(1) Excoriation 0(0) 1(1) 0(0) 3(3…”
Pawaskar, M. D., Bilir, S. P., KOWAL, S. L., González, C. D., Rajpathak, S. N., & Davies, G. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13618 · Cited by 11
Hamarneh, Y. N. A., Marra, C. A., Gniadecki, R., Keeling, S., Morgan, A., & Tsuyuki, R. T. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043612 · Cited by 12
Advanced Glycations End Products in the Skin as Biomarkers of Cardiovascular Risk in Type 2 Diabetes
Planas, A., Simó‐Servat, O., Hernández, C., & Simó, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116234 · Cited by 11
Ipadeola, A., & Adeleye, J. O. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.08.011 · Cited by 11
Cardiovascular risk stratification in diabetic patients
Petretta, M., Acampa, W., Fiumara, G., & Cuocolo, A. (2013) · Clinical and Translational Imaging · doi:10.1007/s40336-013-0032-0 · Cited by 12
“Of these latter, only two prediction models were developed in patients with newly diagnosed diabetes [38, 39], while the others concerned subjects with varying duration of diagnosed diabetes.”
BackgroundPredicted risk of coronary heart disease among persons with type 2 diabetes
Kirk, J. K., Bertoni, A. G., Case, D., Bell, R. A., Goff, D. C., & Narayan, K. M. V. (2007) · Coronary Artery Disease · doi:10.1097/mca.0b013e3282f0902b · Cited by 11
Continuous glucose monitoring in acute coronary syndrome
Rodríguez-Quintanilla, K. A., Lavalle-Gonzalez, F. J., Mancillas‐Adame, L. G., Zapata-Garrido, A. J., Villarreal‐Pérez, J. Z., & Tamez-Pérez, H. E. (2013) · Archivos de cardiología de México · doi:10.1016/j.acmx.2013.08.001 · Cited by 12
Owolabi, M. O., & Ipadeola, A. (2012) · PubMed · Cited by 15
Lobo, J. M., Denton, B. T., Wilson, J. R., Shah, N. D., & Smith, S. A. (2017) · IISE Transactions on Healthcare Systems Engineering · doi:10.1080/24725579.2017.1346728 · Cited by 12
“The transition probabilities for stroke and CHD events were derived from the UKPDS risk models (Kothari et al., 2002; Stevens et al., 2001), and the probabilities for death from other causes were calculated from the CDC mortality tables (National Center for Health Statistics, 2007).”
BackgroundMethodLuque‐Ramírez, M., & de Burgoa, V. S. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.04.014 · Cited by 13
Ezenwaka, C. E., Nwagbara, E., Seales, D., Okali, F., Hussaini, S. A., Raja, B., Jones-LeCointe, A., Sell, H., Avci, H., & Eckel, J. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.12.005 · Cited by 11
Siyambalapitiya, S., Bulugahapitiya, U., Sithole, J., Song, S. H., Fernando, D. J. S., & IDRIS, I. R. (2007) · Diabetes Care · doi:10.2337/dc07-0439 · Cited by 12
“First, it has been validated in the U.K. population (28,29); and second, it has been shown to provide a CVD risk estimate that is equivalent to that of the UKPDS engine when assessing risk 20% over 10 years (17,29).”
MethodZhao, X. Y., Duan, W., Sun, C., Li, Z., Liu, Y., Xiao, X., Wang, G., Gang, X., & Wang, G. (2017) · Journal of Diabetes Research · doi:10.1155/2017/5612049 · Cited by 11
“Thereafter, in order to estimate the CVD risk specially for T2DM patients, Stevens and his colleagues presented the UKPDS risk engine tool which was suitable for T2DM patients after adding HbA1c and DM duration [8].”
MethodCost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in Germany
Shearer, A. T., Bagust, A., Liebl, A., Schoeffski, O., & Goertz, A. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624001-00004 · Cited by 11
Suliman, A., Masud, M. M., Serhani, M. A., Abdullahi, A. S., & Oulhaj, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-082654 · Cited by 10
Rossom, R. C., O’Connor, P. J., Crain, A. L., Waring, S. C., Ohnsorg, K. A., Taran, A. M., Kopski, K. M., & Sperl‐Hillen, J. M. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.105964 · Cited by 10
Ke, Z., Zhou, X., Sun, F., Li, F., Tong, W., & Zhu, Z. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.11.019 · Cited by 10
Oulhaj, A., Aziz, F., Suliman, A., Iqbal, N., Coleman, R. L., Holman, R. R., & Sourij, H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14975 · Cited by 10
“The UKPDS Risk Engine uses two to six repeated measurements for modifiable risk factors to estimate outcomes.(4) In recent years, a newly developed survival model class, “joint models for longitudinal and time-to-event data”, has gained attention in the field of biomedicine for modelling and incorporating repeated ris…”
MethodMaddaloni, E., Nguyen, M., Shah, S. H., & Holman, R. R. (2024) · Diabetes Care · doi:10.2337/dc24-1455 · Cited by 10
Kengne, A. P., NJAMNSHI, A. K., & Mbanya, J. C. (2008) · Clinical medicine Cardiology · doi:10.4137/cmc.s576 · Cited by 10
“The current diabetes specifi c risk models derived from the UKPDS tool (Stevens et al. 2001; Kothari et al. 2002; Donnan et al. 2006; Yang et al. 2007).”
Sosner, P., Hulin-Delmotte, C., Saulnier, P., Cabasson, S., Gand, E., Torremocha, F., Piguel, X., Miot, A., Maréchaud, R., Herpin, D., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.09.012 · Cited by 10
Welschen, L. M. C., Bot, S. D. M., Dekker, J. M., Timmermans, D. R. M., van der Weijden, T., & Nijpels, G. (2010) · BMC Public Health · doi:10.1186/1471-2458-10-457 · Cited by 12
“Appropriateness of risk perception will be assessed by a comparison of the UKPDS score [44] of the patient with the risk perception.”
MethodInfluentialA Review of Risk Factors and Cardiovascular Disease in Diabetes Care - 2011
Nilsson, P. M., & Cederholm, J. (2011) · European Journal of Cardiovascular Medicine · doi:10.5083/ejcm.20424884.43 · Cited by 11
Residual Vascular Risk in T2DM: The Next Frontier
Michel, P., Sylvie, A., & Michel, F. (2011) · InTech eBooks · doi:10.5772/22716 · Cited by 10
Isaman, D. J. M., Barhak, J., & Ye, W. (2009) · Statistics in Medicine · doi:10.1002/sim.3599 · Cited by 11
“We desired to use the method in [12] to combine these data into a single model of diabetes progression; however, one important study, the UKPDS [11], provided a risk equation rather than the cumulative counts.”
MethodInfluentialGuaricci, A. I., Santis, D. D., Carbone, M., Muscogiuri, G., Guglielmo, M., Baggiano, A., Serviddio, G., & Pontone, G. (2018) · BioMed Research International · doi:10.1155/2018/8927281 · Cited by 10
On the validity of time‐dependent AUC estimation in the presence of cure fraction
Beyene, K. M., Ghouch, A. E., & Oulhaj, A. (2019) · Biometrical Journal · doi:10.1002/bimj.201800376 · Cited by 11
Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence
Al‐Sofiani, M. E., Derenbecker, R., Quartuccio, M., & Kalyani, R. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1206-6 · Cited by 13
Wan, Q., Harris, M., Zwar, N. A., Vagholkar, S., & Campbell, T. (2010) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2009.01170.x · Cited by 14
Yang, Ye, Pomerantz, K. B., & Stewart, M. W. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s43724 · Cited by 10
“The UKPDS risk engine has been considered a useful tool for assessing cardiovascular risk and identifying highrisk individuals among newly diagnosed patients having no previous history of cardiovascular disease.(18,19) However, the generalizability of the UKPDS model for use in the broader population of subjects with…”
MethodHernáez, R., Choque, L., Giménez, M., Costa, Á., Márquez, J. I., & Conget, I. (2004) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(06)60633-6 · Cited by 10
A Predictive Neural Network Control Approach in Diabetes Management by Insulin Administration
Alamaireh, M. F. (2006) · doi:10.1109/ictta.2006.1684626 · Cited by 11
“Poor diabetic control may lead to many complications like retinopathy, neuropathy, and nephropathy, while an insulin overdose may result in hypoglycemia that leads to coma [1,2,3,4].”
BackgroundKhunti, K., HERTZ, C. L., Husemoen, L. L. N., Mocevic, E., Nordsborg, R. B., Piltoft, J. S., & Bain, S. C. (2021) · Diabetic Medicine · doi:10.1111/dme.14697 · Cited by 10
Mahmarian, J. J. (2007) · Current Cardiology Reports · doi:10.1007/bf02938339 · Cited by 10
Roze, S., Valentine, W. J., Evers, T., & Palmer, A. J. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x115531 · Cited by 10
Franco, L. F., Szarf, G., Dotto, R. P., Dib, S. A., Moises, R. S., Giuffrida, F. M. A., & Reis, A. F. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108867 · Cited by 9
Lee, J., Choi, Y., Ko, T., Lee, K., Shin, J., & Kim, H.-S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1739 · Cited by 9
Sibarani, M. H. R., Wijaya, I. P. E. K., Rizka, A., Soewondo, P., Riyadina, W., Rahajeng, E., Sudikno, S., Harbuwono, D. S., & Tahapary, D. L. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102330 · Cited by 9
RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
Saboo, B., Agarwal, S., Makkar, B. M., Chawla, R., Ghosh, S. K., Viswanathan, V., Gupta, S., Kumar, C. V., Maheshwari, A., Sreenivasamurthy, L., et al. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01063-6 · Cited by 11
Endocan is Related to Increased Cardiovascular Risk in Type 2 Diabetes Mellitus Patients
Klisic, A. N., Kotur‐Stevuljević, J., & Ninić, A. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0050 · Cited by 9
EASD, E. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0289 · Cited by 13
on behalf RedGDPS Study Group, Rodríguez‐Poncelas, A., de Tuero, G. C., Sáez, M., Garrido-Martín, J. M., Millaruelo-Trillo, J. M., Barrot, J., & Franch‐Nadal, J. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0120-3 · Cited by 10
“Other risk models, such as the UK Prospective Diabetes Study (UKPDS) [18] and the Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation (ADVANCE) [19], have been developed exclusively on a DM2 patient cohort.”
MethodFindeisen, H. M., Weckbach, S., Stark, R. G., Reiser, M. F., Schoenberg, S. O., & Parhofer, K. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-44 · Cited by 11
“To further validate the MRA-score, we analyzed the association of the score with cardiovascular risk calculations in T2DM patients, using the United Kingdom Prospective Diabetes Study (UKPDS) risk engine [24].”
MethodEthical issues in cardiovascular risk management
Loon, M. S. K.-V., Vries, A. V. D., van der Weijden, T., Elwyn, G. J., & Widdershoven, G. A. M. (2013) · Nursing Ethics · doi:10.1177/0969733013505313 · Cited by 9
Jiao, F., Wan, E. Y. F., Fung, C. S. C., Chan, A. K. C., McGhee, S. M., Kwok, R. L. P., & Lam, C. L. K. (2018) · Endocrine · doi:10.1007/s12020-018-1727-9 · Cited by 10
Noh, M., Kwon, H., Jung, C. H., Lee, S., Lee, J., Kim, M.-J., Han, Y., Kwon, T., & Cho, Y. (2019) · Medicine · doi:10.1097/md.0000000000014742 · Cited by 9
Dong, W., Wan, E. Y. F., Bedford, L. E., Wu, T., Wong, C. K. H., Tang, E. H. M., & Lam, C. L. K. (2020) · Public Health · doi:10.1016/j.puhe.2020.06.020 · Cited by 9
GPs’ familiarity with and use of cardiovascular clinical prediction rules: a UK survey study
Ban, J.-W., Perera, R., & Stevens, R. (2020) · BJGP Open · doi:10.3399/bjgpopen20x101081 · Cited by 9
Self-citationNéri, A. K. M., da Silva, G. B., Meneses, G. C., Martins, A. M. C., Daher, E. D. F., Lino, D. O. D. C., Silva, R. P., Nunes, M. D. P. S. F., Alencar, R. L., Rodrigues, M. S., et al. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0611 · Cited by 10
Potential economic impact of increasing low dose aspirin usage on CVD in the US
Manson, S. C., Benedict, Á., Pan, F., Wittrup-Jensen, K. U., & Fendrick, A. M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.514481 · Cited by 10
Tran, A. T., Straand, J., Dalen, I., Birkeland, K. I., Claudi, T., Cooper, J. G., Meyer, H. E., & Jenum, A. K. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-182 · Cited by 9
“To estimate individual 10-year absolute risk for CHD for patients without prior CVD in the two largest ethnic groups (Norwegians and South Asians), we used the UKPDS Risk Engine version 2 [24], which includes age, gender, diabetes duration, HbA1c, SBP, total cholesterol, HDL-cholesterol, smoking status (never, past or…”
MethodAvaliação do risco cardiovascular - Metodologias e suas implicações na prática clínica
Familiar, A. D. M. G. E., Mafra, F., Oliveira, H., & Familiar, A. D. M. G. E. (2008) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v24i3.10509 · Cited by 9
Ramezani‐Jolfaie, N., Aghaei, S., Yazd, E. F., Moradi, A., Mozaffari–Khosravi, H., Zimorovat, A., Raeisi‐Dehkordi, H., Moghtaderi, F., Amiri, M., Ardakani, S. A. Y., et al. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.05.016 · Cited by 9
Choo, E. H., Kim, J.-J., Hwang, B., Choi, I. J., Chang, M., Lim, S., Koh, Y., Park, H., Kim, P.-J., Lee, S., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.04.001 · Cited by 9
“Older age, male sex, and a longer duration of diabetes were also cardiovascular risk factors in the United Kingdom Prospective Diabetes Study [27].”
BackgroundCardiovascular risk prediction tools made relevant for GPs and patients
de Vries, T. I., & Visseren, F. L. J. (2020) · Heart · doi:10.1136/heartjnl-2019-316377 · Cited by 9
Holdich, P. (2009) · Practice Nursing · doi:10.12968/pnur.2009.20.1.37434 · Cited by 9
Shearer, A. T., Bagust, A., Ampudia‐Blasco, F. J., Martinez-Lage, B., Pérez-Escolano, I., & París, G. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624001-00005 · Cited by 9
Vascular risk screening: possible or too much, too soon?
Wierzbicki, A. S., & Reynolds, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02111.x · Cited by 9
Metadata
- Authors
- STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M.
- Affiliations
- University of Oxford (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2001-12-01
- Volume
- 101
- Issue
- 6
- Pages
- 671
- ISSN
- 0143-5221 (ISSN-L)
- OpenAlex
- W2117191092
- Cited by
- 1,084
- References
- 51
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 10 · 2023: 33 · 2022: 44 · 2021: 60 · 2020: 46 · 2019: 42 · 2018: 47 · 2017: 42 · 2016: 39 · 2015: 60 · 2014: 66 · 2013: 68 · 2012: 59
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- coronary artery disease, type 2 diabetes, cardiovascular risk prediction, risk prediction model, glycemia, systolic blood pressure, serum lipids, primary prevention, smoking, sex differences
- MeSH terms
- Adult, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Lipids, Male, Middle Aged, Risk Factors, Smoking, Models, Statistical, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.